In light of the offers and interests received so far,
Elan Corporation, plc
) recently announced that it is gearing up for a formal sale
process. Elan share prices shot up significantly following the
Elan also advised its shareholders not to tender Royalty Pharma's
latest offer of $13.00 per share in cash, along with a contingent
value right (CVR) of up to $2.50 per share. However, Elan stated
in its press release that it will invite Royalty Pharma to
participate in the sale process.
We remind investors that not so long ago the Board of Directors
of Elan rejected Royalty Pharma's latest offer to acquire all its
shares stating that the offer of $13 plus an up to $2.50 CVR
substantially undervalued the company. The previous three offers
of $12.50 per share, $11.25 per share and $11.00 per share were
Meanwhile, Elan's shareholders rejected the majority of the
company's proposed strategic transactions at the Extraordinary
General Meeting (EGM). The shareholders turned down the proposed
acquisition of AOP Orphan Pharmaceuticals and the
) transaction. Moreover, the proposed divestment of the company's
pipeline candidate ELND005 (agitation/aggression in Alzheimer's
disease and Downs Syndrome) was also rejected.
However, the shareholders approved the company's proposed $200
million share repurchase program.
We remind investors that in Apr 2013 Elan sold its Tysabri stake
Biogen Idec Inc.
). Elan currently receives royalty payments at 12% on worldwide
net sales of the multiple sclerosis drug. After the first year,
Elan is expected to receive a royalty of 18% on up to $2 billion
of global net sales of Tysabri and 25% thereafter on over $2
billion of global net sales of Tysabri.
Elan presently carries a Zacks Rank #2 (Buy). However,
Jazz Pharmaceuticals Public Limited Company
) currently looks better positioned with a Zacks Rank #1 (Strong
BIOGEN IDEC INC (BIIB): Free Stock Analysis
ELAN CP PLC ADR (ELN): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
THERAVANCE INC (THRX): Free Stock Analysis
To read this article on Zacks.com click here.